SCHEMBL3833591

SCHEMBL3833591

CCOC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(SC(C)C)C(=O)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 4/20 0.40
ITGA4 P13612 4/20 0.40
ELANE P08246 1/20 0.35
HDAC3 O15379 3/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC6 Q9UBN7 3/20 0.33
MAPT P10636 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
WNT3A P56704 1/20 0.31
NPR3 P17342 2/20 0.31
XDH P47989 1/20 0.31
LMNA P02545 1/20 0.31
CYP2C8 P10632 1/20 0.30
ADORA3 P0DMS8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978080 0.90 ITGB1 (0.45) ITGB1ITGA4CYP3A4CYP2C9NPR3
SCHEMBL3836401 0.90 ITGB1 (0.51) ITGB1ITGA4CYP3A4CYP2C9
SCHEMBL6131688 0.89 ITGB1 (0.44) ITGB1ITGA4ELANEHDAC3HDAC1
SCHEMBL3836314 0.89 ITGB1 (0.44) ITGB1ITGA4ELANEHDAC3HDAC1
SCHEMBL2978337 0.81 ITGB1 (0.58) ITGB1ITGA4CYP3A4CYP2C9
SCHEMBL3884133 0.81 ITGB1 (0.58) ITGB1ITGA4CYP3A4CYP2C9
SCHEMBL3836794 0.81 ITGA4 (0.43) ITGB1ITGA4ELANEHDAC3HDAC1
SCHEMBL3835544 0.81 ITGB1 (0.51) ITGB1ITGA4CYP3A4CYP2C9
Ucb-1184197 SCHEMBL6131680 0.81 ITGB1 (0.47) ITGB1ITGA4CYP3A4CYP2C9
Ucb-1184197 SCHEMBL3833843 0.81 ITGB1 (0.47) ITGB1ITGA4CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501437-B2 Phenylalanine enamide derivatives UCB PHARMA, S.A. (BE) 2009-03-10 US disclosed
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed
EP-1370531-B1 PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS CELLTECH R&D LTD (GB) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 ITGB1 3/4885ITGA4 40/4885ELANE 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.